Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression

Maike Michel1, Bernd L Fiebich2, Hanna Kuzior2

  • 1Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany. maike.michel@uniklinik-freiburg.de.

Insights

This study found higher levels of glial fibrillary acidic protein (GFAP) in the cerebrospinal fluid (CSF) of patients with unipolar depression, suggesting altered microglial activity. S100B levels did not differ significantly, but correlated with CSF barrier integrity markers.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Biochemistry

Background:

  • Inflammatory processes and altered microglial activity are implicated in depressive disorders.
  • Glial fibrillary acidic protein (GFAP) and S100B are known microglial markers.
  • Previous studies examined GFAP and S100B in serum and tissue, but not cerebrospinal fluid (CSF) of depressed patients.

Purpose of the Study:

  • To investigate GFAP and S100B levels in the CSF of patients with major depression.
  • To elucidate the role of these microglial markers in the pathophysiology of affective disorders.

Main Methods:

  • Retrospective study of 102 patients with unipolar depression and 39 healthy controls.
  • Measurement of GFAP and S100B levels in CSF using ELISA kits.
  • Comparison of GFAP/S100B levels between groups and correlation analysis with CSF routine parameters.

Main Results:

  • Significantly higher GFAP levels were observed in patients with unipolar depression compared to controls (p < 0.001).
  • S100B levels did not significantly differ between patients and controls (p = 0.385).
  • GFAP levels correlated positively with albumin quotients; S100B levels correlated with white blood cell counts, total protein, and albumin quotients in CSF.

Conclusions:

  • Elevated GFAP levels in depressed patients may indicate altered microglial and astrocyte activity.
  • S100B levels in CSF may be associated with the integrity of the blood-brain/CSF barrier.
  • Further multimodal and longitudinal studies are needed to validate findings and understand underlying biological mechanisms.